Corcept Therapeutics

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

Retrieved on: 
Wednesday, March 30, 2022

As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.

Key Points: 
  • As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.
  • In this large, randomized study, women with recurrent, platinum-resistant ovarian cancer who were administered relacorilant at the time they received nab-paclitaxel exhibited meaningful improvements in progression free survival, duration of response and overall survival without increased side effects compared to women who received nab-paclitaxel alone.
  • No approved therapy has been shown to significantly extend survival compared to standard chemotherapy in women with platinum-resistant ovarian cancer.
  • Fourteen additional women in the intermittent arm and nine additional women in the comparator arm are expected to contribute to the final overall survival results.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Verra, Core Scientific, and Applied Therapeutics and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 26, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Core Scientifics stock fell $0.72, or 9%, to close at $6.98 on March 3, 2022, thereby injuring investors.
  • For more information on the Applied Therapeutics investigation go to: https://bespc.com/cases/APLT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Porch, Virgin Galactic, Corcept, and Verra and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 21, 2022

Porch Group is a vertical software platform for the home, providing software and services to home services companies.

Key Points: 
  • Porch Group is a vertical software platform for the home, providing software and services to home services companies.
  • On March 1, 2022, after the market closed, Porch Group disclosed that it could not timely file its 2021 annual report.
  • The Company also disclosed that it had identified material weaknesses in its internal control over financial reporting.
  • On this news, Verra Mobilitys stock dropped as much as 7.6% during intraday trading on February 28, 2022, thereby injuring investors.

Bragar Eagel & Squire, P.C. Is Investigating Verra, Corcept, Core Scientific, and Applied Therapeutics and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 15, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Verra Mobilitys stock dropped as much as 7.6% during intraday trading on February 28, 2022, thereby injuring investors.
  • On this news, Core Scientifics stock fell $0.72, or 9%, to close at $6.98 on March 3, 2022, thereby injuring investors.
  • For more information on the Applied Therapeutics investigation go to: https://bespc.com/cases/APLT
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Medallion, Clariant, and Anavex and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 10, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Anavex investigation go to: https://bespc.com/cases/AVXL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Corcept, and Clariant and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 5, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The DOJ is investigating business practices related to CareDxs kidney testing and phlebotomy services.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • On this news, shares of Clariant AG ADR shares fell more than 14% in intraday trading on February 14, 2022.

Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022

Retrieved on: 
Tuesday, March 1, 2022

MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program.

Key Points: 
  • MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program.
  • Corcept will present results from the companys 178-patient, randomized, controlled, Phase 2 study of relacorilant plus nab-paclitaxel for treatment of patients with advanced, platinum-resistant ovarian cancer.
  • Corcept is completing a 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian, adrenal and prostate cancer and Cushings syndrome.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Inc., Medallion Financial, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 28, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 22, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 17, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Agrifys common stock price fell sharply during intraday trading on December 16, 2021.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.